

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents
United States Patent and Trademark
Office
Box PCT
Washington, D.C.20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 07 June 2000 (07.06.00)	
International application No. PCT/SE99/01671	Applicant's or agent's file reference P15605PC/JF
International filing date (day/month/year) 23 September 1999 (23.09.99)	Priority date (day/month/year) 25 September 1998 (25.09.98)
Applicant OLMARKER, Kjell et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

29 March 2000 (29.03.00)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was

☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer F. Baechler Telephone No.: (41-22) 338.83.38
--	--

1
INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 99/01671

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61K 31/65, A61K 31/56, A61K 31/33, A61K 31/16, A61K 31/19, A61P 25/00
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61K, A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
(1) D1 X.	STN International, File MEDLINE, MEDLINE accession no. 97218877, Document no. 97218877, Schlumpf U et al: "Acute lumbar disk displacement with nerve root compression. Indications for peridural steroid injection."; SCHWEIZERISCHE RUNDSCHAU FUR MEDIZIN PRAXIS, (1997 Feb 18) 86 (8) 292-5 --	1,6-8
(2) D2 X	STN International, File MEDLINE, MEDLINE accession no. 76231109, Document no. 76231109, Schenk S et al: "Intrathecal cortison injection in lumbar disc problems"; ARCHIV FUR ORTHOPADISCHE UND UNFALL-CHIRURGIE, (1976 Jun 18) 85 (1) 21-31 --	1,6-8

☒ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

13 January 2000

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Date of mailing of the international search report

29 -01- 2000

Authorized officer

Solveig Gustavsson/ELY
Telephone No. +46 8 782 25 00

Har jag
ei fatt

2
INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 99/01671

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
(3) 26 X	STN International, File EMBASE, EMBASE accession no. 97339851, Document no. 1997339851, Kraemer J. et al: "Lumbar epidural perineural injection: A new technique"; European Spine Journal, (1997) 6/5 (357-361) --	1,6-8
(4) 27 X	STN International, File MEDLINE, MEDLINE accession no. 95064276, Document no. 95064276, Olmarker K. et al: "Effects of methylprednisolone on nucleus pulposus-induced nerve root injury"; SPINE (1994 Aug 15) 19 (16) 1803-8 --	1,6-8
(5) 23 X	STN International, File MEDLINE, MEDLINE accession no. 96310878, Document no. 96310878, Pennica, D. et al: "Cardiotrophin-1, a cytokine present in embryonic muscle, supports long-term survival of spinal motoneurons"; NEURON, (1996 Jul) 17 (1) 63-74 --	1,7-8
(6) 24 X	STN International, File MEDLINE, MEDLINE accession no. 1998068711, Document no. 98068711, Sommer C. et al: "A metalloprotease-inhibitor reduces pain associated behavior in mice with experimental neuropathy"; NEUROSCIENCE LETTERS, (1997 Nov 14) 237 (1) 45-8 --	1,4,6-8
(7) 25 X	STN International, File MEDLINE, MEDLINE accession no. 1998173500, Document no. 98173500, Sommer C. et al: "The effect of thalidomide treatment on vascular pathology and hyperalgesia caused by chronic constriction injury of rat nerve"; PAIN, (1998 Jan) 74 (1) 83-91 --	1,4,6-8
(8) 28 P,X	STN International, File MEDLINE, MEDLINE accession no. 1999071916, Document no. 99071916, Olmarker K. et al: "Tumor necrosis factor alpha and nucleus-pulposus-induced nerve root injury"; SPINE, (1998 Dec 1) 23 (23) 2538-44 -- -----	1-3,6-8

har jag
ei fatt

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE99/01671

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 8
because they relate to subject matter not required to be searched by this Authority, namely:
See extra sheet.
2. ☒ Claims Nos.: 1 and 7-8
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
It is not clear from the wording of the claims, what is excluded from or included in the claimed invention.

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE99/01671

Claim 8 relate to a method of treatment of the human or animal body by surgery or by therapy/a diagnostic method practised on the human or animal body/ Rule. 39.1.(iv). Nevertheless, a search has been executed for this claim. The search has been based on the alleged effects of the compound(s)/composition(s).

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

From the INTERNATIONAL BUREAU

To:

AWAPATENT AB
Box 11394
S-404 28 Göteborg
SUÈDE

RECEIVED

JUL 06 2001

TECH CENTER 1600/2900

Date of mailing (day/month/year) 31 January 2001 (31.01.01)	IMPORTANT NOTIFICATION
Applicant's or agent's file reference P15605PC/JF	
International application No. PCT/SE99/01671	International filing date (day/month/year) 23 September 1999 (23.09.99)

1. The following indications appeared on record concerning:									
<input type="checkbox"/> the applicant	<input type="checkbox"/> the inventor <input checked="" type="checkbox"/> the agent <input type="checkbox"/> the common representative								
Name and Address GÖTEBORGS PATENTBYRÅ DAHLS AB Sjöporten 4 S-417 64 Göteborg Sweden	<table border="1"> <tr> <td>State of Nationality</td> <td>State of Residence</td> </tr> <tr> <td colspan="2">Telephone No. 46 31 507700</td> </tr> <tr> <td colspan="2">Facsimile No. 46 31 7790640</td> </tr> <tr> <td colspan="2">Teleprinter No.</td> </tr> </table>	State of Nationality	State of Residence	Telephone No. 46 31 507700		Facsimile No. 46 31 7790640		Teleprinter No.	
State of Nationality	State of Residence								
Telephone No. 46 31 507700									
Facsimile No. 46 31 7790640									
Teleprinter No.									
2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:									
<input checked="" type="checkbox"/> the person <input checked="" type="checkbox"/> the name <input checked="" type="checkbox"/> the address <input type="checkbox"/> the nationality <input type="checkbox"/> the residence									
Name and Address AWAPATENT AB Box 11394 S-404 28 Göteborg Sweden	<table border="1"> <tr> <td>State of Nationality</td> <td>State of Residence</td> </tr> <tr> <td colspan="2">Telephone No. 46 31 63 02 00</td> </tr> <tr> <td colspan="2">Facsimile No. 46 31 63 02 63</td> </tr> <tr> <td colspan="2">Teleprinter No.</td> </tr> </table>	State of Nationality	State of Residence	Telephone No. 46 31 63 02 00		Facsimile No. 46 31 63 02 63		Teleprinter No.	
State of Nationality	State of Residence								
Telephone No. 46 31 63 02 00									
Facsimile No. 46 31 63 02 63									
Teleprinter No.									
3. Further observations, if necessary:									
4. A copy of this notification has been sent to:									
<input checked="" type="checkbox"/> the receiving Office <input type="checkbox"/> the designated Offices concerned <input type="checkbox"/> the International Searching Authority <input checked="" type="checkbox"/> the elected Offices concerned <input checked="" type="checkbox"/> the International Preliminary Examining Authority <input type="checkbox"/> other:									

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Athina Nickitas-Etienne
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TREATY

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

PCT

To:
Göteborgs Patentbyrå Dahls AB
Sjöporten 4
417 64 GÖTEBORG

WRITTEN OPINION

(PCT Rule 66)

14/12-00
Date of mailing
(day/month/year)

30-10-2000

Applicant's or agent's file reference

P15605PC/JF

REPLY DUE

within 45 days
from the above date of mailing

International application No.

PCT/SE99/01671

International filing date (day/month/year)

23.09.1999

Priority date (day/month/year)

25.09.1998

International Patent Classification (IPC) or both national classification and IPC7

A61K 31/65, A61K 31/56, A61K 31/33, A61K 31/16, A61K 31/19, A61P 25/00

Applicant

A+ Science Invest AB et al

1. This written opinion is the first (first, etc.) drawn by this International Preliminary Examining Authority.
2. This opinion contains indications relating to the following items:
 - I ☒ Basis of the report
 - II ☐ Priority
 - III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
 - IV ☐ Lack of unity of invention
 - V ☒ Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
 - VI ☐ Certain documents cited
 - VII ☐ Certain defects in the international application
 - VIII ☐ Certain observations on the international application
3. The applicant is hereby invited to reply to this opinion.

When? See the time limit indicated above. The applicant may, before the expiration of that time limit, request this Authority to grant an extension, see Rule 66.2(d).

How? By submitting a written reply, accompanied, where appropriate, by amendments, according to Rule 66.3. For the form and the language of the amendments, see Rules 66.8 and 66.9.

Also For an additional opportunity to submit amendments, see Rule 66.4.
For the examiner's obligation to consider amendments and/or arguments, see Rule 66.4bis.
For an informal communication with the examiner, see Rule 66.6.

If no reply is filed, the international preliminary examination report will be established on the basis of this opinion.
4. The final date by which the international preliminary examination report must be established according to Rule 69.2 is: 25.01.2001

Name and mailing address of the IPEA/SE

Patent- och registreringsverket

Box 5055

S-102 42 STOCKHOLM

Facsimile No. 08-667 72 88

Telex

17978

PATOREG-S

Authorized officer

Solveig Gustavsson /GH

Telephone No. 08-782 25 00

WRITTEN OPINION

International application No.

PCT/SE99/01671

I. Basis of the report

1. This opinion has been drawn on the basis of (Substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this opinion as "originally filed"):

☒ the international application as originally filed.

☐ the description, pages _____, as originally filed,
pages _____, filed with the demand,
pages _____, filed with the letter of _____.

☐ the claims, Nos. _____, as originally filed,
Nos. _____, as amended under Article 19,
Nos. _____, filed with the demand,
Nos. _____, filed with the letter of _____.

☐ the drawings, sheets/fig _____, as originally filed,
sheets/fig _____, filed with the demand
sheets/fig _____, filed with the letter of _____.

2. The amendments have resulted in the cancellation of:

☐ the description, pages _____
☐ the claims, Nos. _____
☐ the drawings, sheets/fig _____

3. ☐ This opinion has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the supplemental Box (Rule 70.2(c)).

4. Additional observations, if necessary:

WRITTEN OPINION

International application No.

PCT/SE99/01671

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application,☒ claims Nos. 8

because:

☒ the said international application, or the said claims Nos. 8relate to the following subject matter which does not require an international preliminary examination (*specify*):

See PCT Rule 67.1.(iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.

☒ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. 1, 4, 6-8
are so unclear that no meaningful opinion could be formed (*specify*):

see extra sheet

☐ the claims, or said claims Nos. _____ are so inadequately supported
by the description that no meaningful opinion could be formed.

☐ no international search report has been established for said claims Nos. _____

WRITTEN OPINION

International application No.

PCT/SE99701671

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: III

It is not clear from the wording of claims 1 and 7-8, what is excluded from or included in the claimed invention.

Present claims 1,4 and 6-7 relate to a compound/method defined by reference to desirable characteristic, namely TNF-alpha inhibiting activity. The claims cover all compounds having this characteristic, whereas the application provides support within the meaning of Article 6 PCT and /or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support for the whole area of the claimed scope. Independent of the above reasoning, the claims lack clarity (Article 6 PCT). An attempt is made to define the compounds by reference to a result to be achieved.

WRITTEN OPINION

International application No.

PCT/SE99/01671

V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims	<u>2-3, 5</u>	YES
	Claims	<u>1, 4, 6-7</u>	NO
Inventive step (IS)	Claims		YES
	Claims	<u>1-7</u>	NO
Industrial applicability (IA)	Claims	<u>1-7</u>	YES
	Claims		NO

2. Citations and explanations

The claimed invention relates to the use of a TNF-alpha inhibitor for the manufacture of a pharmaceutical composition for treatment of spinal disorders, such as nerve root injury. The TNF-alpha inhibitor is selected from several different groups of compounds.

Present claims 1, 4 and 6-7 relate to a compound/method defined by reference to desirable characteristic, namely TNF-alpha inhibiting activity. The claims cover all compounds having this characteristic, whereas the application provides support within the meaning of Article 6 PCT and /or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support for the whole area of the claimed scope. Independent of the above reasoning, the claims lack clarity (Article 6 PCT). An attempt is made to define the compounds by reference to a result to be achieved.

Therefore, a complete examination report cannot be established for these broad claims.

From the abstracts of STN International, File MEDLINE with Accession numbers: ^{D1}97218877, ^{D2}76231109, ^{D3}96310878, ^{D4}98068711 and ^{D5}98173500 and File EMBASE with Accession number ^{D6}97339851 several of the compounds according to the present claims (hydroxamic acid derivatives, thalidomide, corticosteroids etc.), are known for treatment of nerve injuries and also for treatment of nerve root disorders.

Thus, claims 1, 4 and 6-7 lack novelty and inventive step.

.../...

WRITTEN OPINION

International application No.

PCT/SE99/01671

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: V

From STN International, File MEDLINE, Accession number 07
95064276 the metalloproteinase inhibitor methylprednisolone is
known for treatment of nerve root injury.
Even if methylprednisolone has been excluded from the
selection list of TNF-alpha inhibitors, the use of an TNF-
alpha inhibitor for treatment of nerve root injury is known.
Consequently, claims 1-7 lack inventive step.

Claim 8 is directed to a method for the treatment of a medical
disorder.

For the assessment of the aforesaid claims on the question
whether they are industrially applicable, no unified criteria
exist in the PCT. The patentability can also be dependent upon
the formulation of the claims.

REC'D 24 JAN 2001

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference P15605PC/JF	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/SE99/01671	International filing date (day/month/year) 23.09.1999	Priority date (day/month/year) 25.09.1998
International Patent Classification (IPC) or national classification and IPC ₇ A 61 K 31/65, A 61 K 31/56, A 61 K 31/33, A 61 K 31/16, A 61 K 31/19, A 61 P 25/00		
Applicant A+ Science Invest AB et al		

<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of <u>5</u> sheets, including this cover sheet.</p> <p><input checked="" type="checkbox"/> This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of <u>5</u> sheets.</p>	
<p>3. This report contains indications relating to the following items:</p> <p>I <input checked="" type="checkbox"/> Basis of the report</p> <p>II <input type="checkbox"/> Priority</p> <p>III <input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</p> <p>IV <input type="checkbox"/> Lack of unity of invention</p> <p>V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</p> <p>VI <input type="checkbox"/> Certain documents cited</p> <p>VII <input type="checkbox"/> Certain defects in the international application</p> <p>VIII <input type="checkbox"/> Certain observations on the international application</p>	

Date of submission of the demand 29.03.2000	Date of completion of this report 17.01.2001
Name and mailing address of the IPEA/SE Patent- och registreringsverket Box 5055 S-102 42 STOCKHOLM Facsimile No. 08-667 72 88	Authorized officer Solveig Gustavsson/EÖ Telephone No. 08-782 25 00

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/SE99/01671

I. Basis of the report

1. With regard to the **elements** of the international application:*

- ☐ the international application as originally filed
- ☒ the description:
 pages 1-21, as originally filed
 pages _____, filed with the demand
 pages _____, filed with the letter of _____
- ☒ the claims:
 pages _____, as originally filed
 pages _____, as amended (together with any statement) under article 19
 pages _____, filed with the demand
 pages 22-26, filed with the letter of 22/12 2000
- ☐ the drawings:
 pages _____, as originally filed
 pages _____, filed with the demand
 pages _____, filed with the letter of _____
- ☐ the sequence listing part of the description:
 pages _____, as originally filed
 pages _____, filed with the demand
 pages _____, filed with the letter of _____

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language _____ which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. ☐ The amendments have resulted in the cancellation of:

- ☐ the description, pages _____
- ☐ the claims, Nos. _____
- ☐ the drawings, sheet/fig _____

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2 (c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item I and annexed to this report.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/SE99/01671

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application,
- ☒ claims Nos. 11-14, 19-34

because:

- ☒ the said international application, or the said claims Nos. 19-34
relate to the following subject matter which does not require an international preliminary examination (*specify*):

See PCT Rule 67.1.(iv).: Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.

- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. _____
are so unclear that no meaningful opinion could be formed (*specify*):

- ☐ the claims, or said claims Nos. _____ are so inadequately supported
by the description that no meaningful opinion could be formed.

- ☒ no international search report has been established for said claims Nos. 11-14

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

- ☐ the written form has not been furnished or does not comply with the standard.
- ☐ the computer readable form has not been furnished or does not comply with the standard.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/SE99/01671

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. Statement**

Novelty (N)	Claims	<u>1-10</u>	YES
	Claims	<u>15-18</u>	NO
Inventive step (IS)	Claims	<u>1-10</u>	YES
	Claims	<u>15-18</u>	NO
Industrial applicability (IA)	Claims	<u>1-10, 15-18</u>	YES
	Claims	<u></u>	NO

2. Citations and explanations (Rule 70.7)

A set of new claims has been filed with the letter of 22 December 2000. The original claims 1-6 have resulted in the new claims 1-10, the original claim 7 has resulted in the new claims 11-14 and the original claim 8 has resulted in the new claims 19-34. Further, some additional claims 15-18 concerning a pharmaceutical composition have been added.

The claimed invention relates to the use of a TNF-alpha inhibitor for the manufacture of a pharmaceutical composition for treatment of spinal disorders, such as nerve root injury. The TNF-alpha inhibitor is selected from several different groups of compounds.

The former claim 7 was dependent of claim 1 and thus directed to TNF-alpha inhibitors. The new corresponding claims 11-14 are independent of claim 1 and directed to other compounds than TNF-alpha inhibitors.

Thus, the invention according to claims 11-14 must be considered to lack unity in relation to the invention according to the rest of the claims (claims 1-14 and 19-34). However, no search report has been established for these claims in their present wording and therefore these claims will not be regarded in this examination report.

Claims 1-10 relates to the use of TNF-alpha inhibitors, for the manufacture of pharmaceutical compositions, for the treatment of spinal disorders caused by TNF-alpha.

The closest prior is considered to be the abstract of STN international, File MEDLINE, Accession number No. 95064276.

.../...

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: V

This document shows the use of methylprednisolone for the treatment of nerve root effects affected by nucleus pulposus. However, this document does not indicate any relation between spinal disorders and TNF-alpha.

Neither do any of the other cited documents indicate such a relation between spinal disorders and TNF-alpha.

Consequently claims 1-10 are considered to fulfil the requirements of novelty, inventive step and industrial applicability.

The new claims 15-18 relate to pharmaceutical compositions containing the exemplified TNF-alpha inhibitors. These compounds or group of compounds are already known in pharmaceutical compositions (as is disclosed in the description) and the new use does not limit the scope of these claims. Thus, claims 15-18 lack novelty.

Claims 1-10 relate to the use of a substance for the manufacture of medicaments with specific medical qualities (so-called "second medical indication"). Claims of this kind may be accepted and examined in some countries. Owing to the difference in national practice and laws, it is not possible for the International Preliminary Examining Authority to give a valid statement on such claims. The consideration given is based on the acceptance of such claims according to national legislation

Claims 19-34 are directed to a method for the treatment of a medical disorder.

For the assessment of the aforesaid claims on the question whether they are industrially applicable, no unified criteria exist in the PCT. The patentability can also be dependent upon the formulation of the claims.

Most countries do not recognise as industrially applicable the subject-matter of claim directed to treatment of medical disorders or to the use of a compound in medical treatment. However, they will allow, claims to a known compound for first use in medical treatment (first medical indication) and the use of such a compound for the manufacture of a medicament for a new medical treatment (second medical indication).

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 31/65, 31/56, 31/33, 31/16, 31/19, A61P 25/00	A1	(11) International Publication Number: WO 00/18409 (43) International Publication Date: 6 April 2000 (06.04.00)
(21) International Application Number: PCT/SE99/01671 (22) International Filing Date: 23 September 1999 (23.09.99) (30) Priority Data: 9803276-6 25 September 1998 (25.09.98) SE 9803710-4 29 October 1998 (29.10.98) SE (71) Applicant (for all designated States except US): A+ SCIENCE INVEST AB [SE/SE]; P.O. Box 3096, S-400 10 Göteborg (SE). (72) Inventors; and (75) Inventors/Applicants (for US only): OLMARKER, Kjell [SE/SE]; Gustavsgatan 35, S-431 66 Mölndal (SE). RYDEVIK, Björn [SE/SE]; Laboratorietrappan 6, S-412 68 Göteborg (SE). (74) Agent: GÖTEBORGS PATENTBYRÅ DAHLS AB; Sjöporten 4, S-417 64 Göteborg (SE).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: USE OF CERTAIN DRUGS FOR TREATING NERVE ROOT INJURY		
(57) Abstract The present invention relates to pharmaceutical compositions for the treatment of spinal disorders caused by the liberation of TNF- α comprising an effective amount of a TNF- α inhibitor, as well as method for treatment of such disorders, and the use of TNF- α inhibitors in the preparation of pharmaceutical composition for such treatment.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

TITLE**USE OF CERTAIN DRUGS FOR TREATING NERVE ROOT INJURY****DESCRIPTION**5 **Technical field**

The present invention relates to the use of a TNF- α inhibitor in the preparation of pharmaceutical compositions for the treatment of nerve root injury, as well as a method for treating nerve root injury.

10 The object of the present invention is to obtain a possibility to treat nerve root injury induced by disk herniation, which may turn up as radiating pain into the arm or leg (sciatica), by blocking disk related cytokines.

Background of the invention

15 Disk herniation is a troublesome disorder, which can cause pronounced pain and muscle dysfunction, and thereby loss of ability to work. A herniation may occur in any disk in the spine but herniations in the lumbar and the cervical spine are most common. A disk herniation in the cervical spine may induce radiating pain and muscle dysfunction in the arm and herniation in the lumbar spine may induce radiating pain and muscle dysfunction in the
20 leg. The radiating pain in the leg is generally referred to as "sciatica". Disk herniation will cause trouble to a varying degree, and the pain may last for one or two months or in severe cases up to 6 months. The arm or leg pain that can occur as a result of disk herniation can be very intense and may thus affect the individual patient's whole life situation during the sickness period.

25

US-A-5,703,092 discloses the use of hydroxamic acid compounds and carbocyclic acids as metalloproteinase and TNF inhibitors, and in particular in treatment of arthritis and other related inflammatory diseases. No use of these compounds for the treatment of nerve root injuries is disclosed or hinted at.

30

US-A-4,925,833 discloses the use of tetracyclines to enhance bone protein synthesis, and treatment of osteoporosis.

US-A-4,666,897 discloses inhibition of mammalian collagenolytic enzymes by tetracyclines. The collagenolytic activity is manifested by excessive bone resorption, periodontal disease, rheumatoid arthritis, ulceration of cornea, or resorption of skin or other connective tissue collagen.

5

Neither of these latter two documents mentions nerve root injury or the treatment thereof.

Description of the present invention

It has now surprisingly been shown possible to be able to treat nerve root injuries, or at least
10 alleviate the symptoms of nerve root injuries by using a pharmaceutical composition comprising an therapeutically active amount of a TNF- α inhibitor selected from the group consisting of metalloproteinase inhibitors excluding methylprenisolone, tetracyclines including chemically modified tetracyclines, quinolones, corticosteroids, thalidomide, lazaroïdes, pentoxiphylline, hydroxamic acid derivatives, naphopyrans, soluble cytokine
15 receptors, monoclonal antibodies towards TNF- α , amrinone, pimobendan, vesnarinone, phosphodiesterase III inhibitors, lactoferrin and lactoferrin derived analogous, and melatonin in the form of bases or addition salts together with a pharmaceutically acceptable carrier.

The therapeutically effective amount is a dosage normally used when using such compounds
20 for other therapeutic uses. Many of these drugs are commercially known registered drugs.

Compounds that possess this activity are tetracyclines, such as tetracycline, doxycycline, lymecycline, oxytetracycline, minocycline, and chemically modified tetracyclines dedimethylaminotetracycline, hydroxamic acid compounds, carbocyclic acids and
25 derivatives, thalidomide, lazaroïdes, pentoxiphylline, naphopyrans, soluble cytokine receptors, monoclonal antibodies towards TNF- α , amrinone, pimobendan, vesnarinone, phosphodiesterase III inhibitors, lactoferrin and lactoferrin derived analogous, melatonin, norfloxacin, ofloxacin, ciprofloxacin, gatifloxacin, pefloxacin, lomefloxacin, and temafloxacin. These can be present as bases or in the form of addition salts, whichever
30 possesses the best pharmaceutical effect, and best property to be brought into a pharmaceutical suitable composition.

Further, the active component comprises a substance inhibiting a compound triggered by the

release of TNF- α , such as interferon-gamma, interleukin-1, and nitrogen oxide (NO) in the form of base or addition salts.

The invention further relates to a method for inhibiting the symptoms of nerve root injury.

5

The effects of doxycycline, soluble cytokine-receptors, and monoclonal cytokine-antibodies have been studied and the methods used and results obtained are disclosed below.

Example

10 Study design.

The effects of nucleus pulposus and various treatments to block TNF- α activity were evaluated in an experimental set-up using immunohistochemistry and nerve conduction velocity recordings.

15 Summary of background data:

A meta-analysis of observed effects induced by nucleus pulposus reveals that these effects might relate to one specific cytokine, Tumor Necrosis Factor alpha (TNF(α)).

Objectives.

20 To assess the presence of TNF(α) in pig nucleus pulposus cells and to see if blockage of TNF(α) also blocks the nucleus pulposus-induced reduction of nerve root conduction velocity.

Methods

25 Series-1: Cultured nucleus pulposus-cells were immunohistologically stained with a monoclonal antibody for TNF(α).

Series-2: Nucleus pulposus was harvested from lumbar discs and applied to the sacro-coccygeal cauda equina in 13 pigs autologously. Four pigs received 100 mg of doxycycline intravenously, 5 pigs had a blocking monoclonal antibody to TNF- α applied locally in the nucleus pulposus, and 4 pigs remained non-treated and formed control. Three days after the application the nerve root conduction velocity was determined over the application zone by local electrical stimulation.

30

Series-3: Thirteen pigs had autologous nucleus pulposus placed onto their sacrococcygeal

cauda equina similar to series-2. Five pigs (bodyweight 25 kg) received Remicade^R (infliximab) 100 mg i.v. preoperatively, and 8 pigs received Enbrel^R (etanercept) 12.5 mg s.c. preoperatively and additionally 12.5 mg s.c. three days after the operation. Seven days after the nucleus pulposus-application the nerve root conduction velocity was determined over the application zone by local electrical stimulation according to series-2.

Results.

Series-1: TNF- α was found to be present in the nucleus pulposus-cells.

Series-2: The selective antibody to TNF- α limited the reduction of nerve conduction velocity, although not statistically significantly to the control series. However, treatment with doxycycline significantly blocked the nucleus pulposus-induced reduction of conduction velocity.

Series-3: Both drugs (infliximab, and etanercept) blocked the nucleus pulposus induced nerve injury efficiently and normal average nerve conduction velocities were found after treatment with both of these two drugs.

Conclusion.

For the first time a specific substance, Tumor Necrosis Factor-alpha, has been linked to the nucleus pulposus-induced effects of nerve roots after local application. Although the effects of this substance may be synergistic with other similar substances, the data of the present study may be of significant importance for the continued understanding of nucleus pulposus' biologic activity, and might also be of potential use for future treatment strategies of sciatica.

After previously being considered as just a biologically inactive tissue component compressing the spinal nerve root at disc herniation, the nucleus pulposus has recently been found to be highly active, inducing both structural and functional changes in adjacent nerve roots when applied epidurally (24,37,38,41,42). It has thereby been established that autologous nucleus pulposus may induce axonal changes and a characteristic myelin injury (24,38,41,42), increased vascular permeability (9,44), intra vascular coagulation (24,36), and that membrane-bound structure or substances of the nucleus pulposus-cells are responsible for these effects (24,37). The effects have also been found to be efficiently blocked by methyl-prednisolone and cyclosporin A (2,38). When critically looking at these data, one realizes that there is at least one cytokine that relates to all of these effects, Tumor Necrosis

Factor alpha (TNF- α). To assess if TNF- α may be involved in the nucleus pulposus induced nerve root injury the presence of TNF- α in nucleus pulposus-cells was assessed and was studied if the nucleus pulposus-induced effects could be blocked by doxycycline, a soluble TNF-receptor, and a selective monoclonal TNF-antibody, the latter administered both locally
5 in the nucleus pulposus and systemically.

MATERIAL AND METHODS

Series-1, Presence of TNF- α in pig nucleus pulposus-cells:

Nucleus pulposus (NP) from a total of 13 lumbar and thoracic discs were obtained from a
10 pig used for other purposes. NP was washed once in Ham's F12 medium (Gibco BRL, Paisley, Scotland) and then centrifuged and suspended in 5 ml of collagenase solution in Ham's F12 medium (0.8 mg/ml, Sigma Chemical Co., St Louis, MO, USA) for 40 minutes, at 37°C in 25 cm² tissue culture flasks. The separated NP-cell pellets were suspended in DMEM/F12 1:1 medium (Gibco BRL, Paisley, Scotland) supplemented with 1% L-
15 glutamine 200 mM (Gibco BRL, Paisley, Scotland), 50µg/ml gentamycine sulphate (Gibco BRL, Paisley, Scotland) and 10% foetal calf serum (FCS), (Gibco BRL, Paisley, Scotland). The cells were cultured at 37°C and 5% CO₂ in air for 3-4 weeks and then cultured directly on tissue culture treated glass slides (Becton Dickinson & Co Labware, Franklin Lakes, NJ, USA). After 5 days on the glass slides, the cells were fixed in situ by acetone for 10
20 minutes. After blocking irrelevant antigens by application of 3% H₂O₂ (Sigma Chemical Co., St Louis, MO, USA) for 30 minutes and Horse Serum (ImmunoPure ABC, peroxidase mouse IgG staining kit nr.32028, Pierce, Rockford, IL) for 20 minutes, the primary antibody (Anti-pig TNF- α monoclonal purified antibody, Endogen, Cambridge, MA, USA) was applied over night at +40°C, diluted at 1:10, 1:20 and 1:40. For control, BSA (bovine serum
25 albumin, Intergen Co, New York, USA) suspended in PBS (phosphate buffered saline, Merck, Darmstadt, Germany) was applied in the same fashion. The next day the cells were washed with 1% BSA in PBS and the secondary antibody (ImmunoPure ABC, peroxidase mouse IgG staining kit nr.32028, Pierce, Rockford, IL) was applied for 30 minutes. To enhance this reaction, the cells were exposed to Avidin-Biotin complex for additionally 30
30 minutes (ImmunoPure ABC, peroxidase mouse IgG staining kit nr.32028, Pierce, Rockford, IL). The cells were then exposed to 20 mg of DAB (3,3-diaminobenzidine tetrahydrochloride nr. D-5905, Sigma Chemical Co., St Louis, MO, USA) and 0.033 ml of 3% H₂O₂ in 10 ml of saline for 10 minutes. The cells were washed in PBS, dehydrated in a

series of ethanol, mounted and examined by light microscopy by an unbiased observer regarding the presence of a brown colouration indicating presence of TNF- α .

Series-2, Neurophysiologic evaluation:

5 Thirteen pigs, (body weight 25-30 kg) received an intramuscular injection of 20 mg/kg body weight of Ketalar^R (ketamine 50 mg/ml, Parke-Davis, Morris Plains, New Jersey) and an intravenous injection of 4 mg/kg body weight of Hypnodil^R (methomidate chloride 50 mg/ml, AB Leo, Helsingborg, Sweden) and 0.1 mg/kg body weight of Stresnil^R (azaperon 2 mg/ml, Janssen Pharmaceutica, Beerse, Belgium). Anaesthesia was maintained by additional intravenous injections of 2 mg/kg body weight of Hypnodil^R and 0.05 mg/kg body weight of Stresnil^R. The pigs also received an intravenous injection of 0.1 mg/kg of Stesolid Novum^R (Diazepam, Dumex, Helsingborg, Sweden) after surgery.

15 Nucleus pulposus was harvested from the 5th lumbar disc through a retro peritoneal approach (42). Approximately 40 mg of the nucleus pulposus was applied to the sacrococcygeal cauda equina through a midline incision and laminectomy of the first coccygeal vertebra. Four pigs did not receive any treatment (no treatment). Four other pigs received an intravenous infusion of 100 mg of doxycycline (Vibramycino, Pfizer Inc., New York, USA) in 100 ml of saline over 1 hour. In 5 pigs, the nucleus pulposus was mixed with 20 100 μ l of a 1,11 mg/ml suspension of the anti-TNF- α antibody used in series 1, before application.

Three days after the application, the pigs were reanaesthetized by an intramuscular injection of 20 mg/kg body weight of Ketalar^R and an intravenous injection of 35 mg/kg body weight of Pentothal^R (Thiopental sodium, Abbott lab, Chicago, IL). The pigs were ventilated on a 25 respirator. Anaesthesia was maintained by an intravenous bolus injection of 100 mg/kg body weight of Chloralose (α -D(+)-gluco-chloralose, Merck, Darmstadt, Germany) and by a continuous supply of 30 mg/kg/hour of Chloralose. A laminectomy from the 4th sacral to the 3rd coccygeal vertebra was performed. The nerve roots were covered with Spongostane^R (Ferrosan, Denmark). Local tissue temperature was continuously monitored and maintained 30 at 37.5-38.0°C by means of a heating lamp.

The cauda equina was stimulated by two E2 subdermal platinum needle electrodes (Grass

Instrument Co., Quincy, MA) which were connected to a Grass SD9 stimulator (Grass Instrument Co., Quincy, MA) and gently placed intermittently on the cauda equina first 10 mm cranial and then 10 mm caudal to the exposed area. To ensure that only impulses from exposed nerve fibres were registered, the nerve root that exited from the spinal canal
5 between the two stimulation sites were cut. An EMG was registered by two subdermal platinum needle electrodes which were placed into the paraspinal muscles in the tail approximately 10 mm apart. This procedure is reproducible and represents a functional measurement of the motor nerve fibres of the cauda equina nerve roots. The EMG was visualized using a Macintosh IIfx computer provided with Superscope software and
10 MacAdios II AID converter (GW Instruments, Sommerville, MA) together with a Grass P18 preamplifier (Grass Instrument Co., Quincy, MA). The separation distance between the first peaks of the EMG from the two recordings was determined and the separation distance between the two stimulation sites on the cauda equina was measured with calipers. The nerve conduction velocity between the two stimulation sites could thus be calculated from
15 these two measurements.

The person performing the neurophysiologic analyses was unaware of the experimental protocol for the individual animal, and after finishing the complete study the data were arranged in the three experimental groups and statistical differences between the groups
20 were assessed by Student's t-test. The experimental protocol for this experiment was approved by the local animal research ethics committee.

Series-3: Thirteen pigs had autologous nucleus pulposus placed onto their sacrococcygeal cauda equina similar to series-2. Five pigs (bodyweight 25 kg) received the human/murine
25 monoclonal antibody Remicade^R (infliximab, Immunex Corporation, Seattle, WA 98101, USA) 100 mg i.v. preoperatively, and 8 pigs received Enbrel^R (etanercept, Centocor B.V., Leiden, the Netherlands) 12.5 mg s.c. preoperatively and additionally 12.5 mg s.c. three days after the operation. Seven days after the nucleus pulposus-application the nerve root conduction velocity was determined over the application zone by local electrical stimulation
30 according to series-2. To blind the study the neurophysiological evaluation was conducted in parallel to another study and the person performing the analyses did not know from which study and what treatment each specific animal was subjected to. No non-treated animals were included in the series-3 due to the pre-existing knowledge of nerve conduction velocity

after seven days of either nucleus pulposus or fat (control) application. The statistical difference between the groups, infliximab, and etanercept, nucleus pulposus without treatment (positive control from previous data) and application of retroperitoneal fat (negative control from previous data) was assessed by using ANOVA and Fisher's PLSD at 5%.

RESULTS

Series-1, Presence of TNF- α in pig nucleus pulposus-cells:

Examples of the light microscopic appearance of the stained glass slides. In the sections using BSA in PBS as "primary antibody" (control) no staining was observed, ensuring that there was no labelling and visualization of irrelevant antigens. When the anti-TNF- α antibody was applied at 1:40 dilution there was only a weak staining. However, the staining increased with diminishing dilutions of the antibody. The staining was seen in the soma of the cells and it was not possible to differentiate whether TNF- α was located in the cytoplasm, on the cell surface bound to the cell-membrane, or both.

Series-2, Neurophysiologic evaluation:

Application of non-modified nucleus pulposus and without any treatment induced a reduction in nerve conduction velocity similar to previous studies (Table 1), whereas treatment with doxycycline completely blocked this reduction ($p < 0.01$ Student's t-test).

Local application of anti-TNF- α -antibody also induced a partial block of this reduction, although not as complete as doxycycline and not statistically significant to the no treatment-series.

Series-3: Treatment with both drugs seemed to prevent the nucleus pulposus-induced reduction of nerve root conduction velocities since the average nerve conduction velocity for both these treatment groups were close to the average conduction of fat-application series as seen in a previous study (Table 2). There was a statistically significant difference to application of nucleus pulposus, but without any treatment, seen for both drugs.

Table 1 - Series-2

<u>Treatment</u>	<u>n</u>	<u>NCV(m/s+SD)</u>
Local anti-TNF- α	5	64 \pm 28
Doxycycline	4	76 \pm 9
No treatment	4	46 \pm 12

Table 2 - Series-3

	<u>Treatment</u>	<u>n</u>	<u>NCV(m/s+SD)</u>
	<i>Fat*</i>	5	76±11
5	Embre ^R	8	78±14
	Remicade ^R	5	79±15
	<i>No treatment*</i>	5	45±19

* Data included from ref. no. 42, Olmarker et al, 1993

10

DISCUSSION

The data of the present study demonstrated that TNF- α may be found in nucleus pulposus-cells of the pig. If TNF- α was blocked by a locally applied selective monoclonal antibody, the nucleus pulposus-induced reduction of nerve root conduction velocity was partially blocked, although no statistically significant compared to the series with non-treated animals. However, if systemic treatments with doxycycline, infliximab, and etanercept were used to inhibit TNF- α , the reduction of nerve conduction velocity was significantly prevented.

20

In recent years, it has been verified that local application of autologous nucleus pulposus may injure the adjacent nerve roots. Thus, it has become evident that the nerve root injury seen at disc herniation may not be solely based on mechanical deformation of the nerve root, but may also be induced by unknown "biochemical effects" related to the epidural presence of herniated nucleus pulposus. Although this new research field has generated many experimental studies, the mechanisms and substances involved are not fully known. It has been seen that local application of autologous nucleus pulposus may induce axonal injury (24,37,38,40-42), a characteristic injury of the myelin sheath (24,38,40-42), a local increase of vascular permeability (9,36,44), intra vascular coagulations, reduction of intra neural blood flow (43), and leukotaxis (36). It has been seen that the nucleus pulposus-related effects may be blocked efficiently by methylprednisolone (38) and cyclosporin A (2), and slightly less efficiently by indomethacin (3), and lidocaine (69). Further, it has been understood that the effects are mediated by the nucleus pulposus-cells (37), particularly by

30

substances or structures bound to the cell-membranes (25). When critically considering these data, it becomes evident that at least one specific cytokine could be related to these observed effects, Tumor Necrosis Factor-alpha (TNF- α). TNF- α may induce nerve injury (29,31,45,50,66) mainly seen as a characteristic myelin injury that closely resembles the nucleus pulposus-induced myelin-injury (29,47,51,54,62,64,66,70). TNF- α may also induce an increase in vascular permeability (47,66) and initiate coagulation (22,34,63). Further, TNF- α may be blocked by steroids (4,8,21,61,68), and cyclosporin A (11,55,67,68). However, the blocking effect on TNF- α is not so pronounced by NSAID (14,17,20) and very low or the opposite by lidocaine (5,32,46,60). It was recently observed that local application of nucleus pulposus may induce pain-related behaviour in rats, particularly thermal hyperalgesia (23,40). TNF- α has also been found to be related to such pain-behaviouristic changes (12,35,56,66), and also to neuropathies in general (30,54,56,57). However there are no studies that have assessed the possible presence of TNF- α in the cells of the nucleus pulposus.

To assess if TNF- α could be related to the observed nucleus pulposus induced reduction in nerve root conduction velocity it was necessary first to analyse if there was TNF- α in the nucleus pulposus-cells. The data clearly demonstrated that TNF- α was present in these cells. TNF- α is produced as precursor (pro-TNF) that is bound to the membrane and it is activated by cleavage from the cell-membrane by a zinc-dependent metallo-endopeptidase (TNF- α converting enzyme, TACE) (6,15,16,48,49). This may thus relate well to experimental findings where application of the mere cell-membranes of autologous nucleus pulposus-cells induced nerve conduction velocity reduction, which indicated that the effects were mediated by a membrane-bound substances. Second, the effects of the TNF- α had to be blocked in a controlled manner. We then first choose to add the same selective antibody that was used for immunohistochemistry in series 1, which is known to also block the effects of TNF- α , to the nucleus pulposus before application. Also, we choose to treat the pigs with doxycycline, which is known to block TNF- α (26,27,33,52,53). However, due to the low pH of the doxycycline preparation it was chosen to treat the pigs by intravenous injection instead of local addition to the nucleus pulposus since nucleus pulposus at a low pH has been found to potentiate the effects of the nucleus pulposus (38,39).

Two recently developed drugs for specific TNF- α inhibition were also included in the study.

Infliximab is a chimeric monoclonal antibody composed of human constant and murine variable regions, and binds specifically to human TNF- α . As opposed to the monoclonal antibody used in series-2 for the 3 days observation period, infliximab was not administered locally in the autotransplanted nucleus pulposus but instead systemically in a clinically recommended dose (4 mg/kg). Etanercept is a dimeric fusion protein consisting of the Fc portion of human IgG. The drug was administered in a dosage comparable to the recommended dose for pediatric use (0.5 mg/kg, twice a week).

The data regarding nerve conduction velocity showed that the reduction was completely blocked by the systemic-treatment and that the nerve conduction velocities in these series were close to the conduction velocity after application of a control substance (retro peritoneal fat) from a previous study (42). Application of the anti-TNF- α -antibody to the nucleus pulposus also partially prevented the reduction in nerve conduction velocity, however, not as pronounced as doxycycline, and the velocity in this series was not statistically different to the velocity in the series with not treated animals, due to the wide deviation of the data.

The fact that the local anti-TNF- α antibody treatment only partially blocked the nucleus pulposus-induced reduction of nerve conduction velocity and the high standard deviation of the data could probably have at least three different explanations. First, if looking at the specific data within this group it was found that the nerve conduction velocity was low in 2 animals (mean 37.5 m/s) and high in 3 animals (mean 81.3 m/s). There are thus 2 groups of distinctly different data within the anti-TNF- α treatment series. This will account for the high standard deviation and might imply that the blocking effect was sufficient in 3 animals and non-sufficient in 2 animals. The lack of effects in these animals could be based simply on the amount of antibodies in relation to TNF- α molecules not being sufficient, and if a higher dose of the antibody had been used, the TNF- α effects would thus have been blocked even in these animals. Such a scenario could then theoretically imply that TNF- α alone is responsible for the observed nucleus pulposus-induced effects, and that this could not be verified experimentally due to the amount of antibody being too low.

Second, it is also known that tetracyclines such as doxycycline and minocycline may block a number of cytokines and other substances. For instance they may block IL-1 (1,28,58),

IFN γ (27), NO-synthetasel, and metalloproteinases (1,53,58). Particularly IL-1 and IFN γ are known to act synergistically with TNF- α and are known to be more or less neurotoxic (7,10,13,18,19,56,59). These substances are also blocked by steroids and cyclosporin A which corresponds well with the previous observations on nucleus pulposus-induced nerve root injury which have shown that the nucleus pulposus-induced effects may be blocked by these substances (8,67). One may therefore also consider the possibility that a selective block of TNF- α may not be sufficient to completely block the nucleus pulposus-induced effects on nerve function, and that simultaneous block of other synergistic substances is necessary as well. Thus, this scenario, on the other hand, implies that TNF- α is not solely responsible for the nucleus pulposus-induced effects, and that other synergistic substances, which are also blocked by doxycycline, may be necessary.

The third explanation could be that the amount of TNF in the nucleus pulposus may well be enough to start the pathophysiologic cascade locally in the nerve root, comprising increased vascular permeability and aggregation and recruitment of systemic leukocytes. However, it is these leukocytes that have the major content of TNF- α and that systemic treatment in a sufficient dose is necessary to block the contribution from these leukocytes, and thereby also blocking the events leading to nerve injury.

TNF- α may have various pathophysiologic effects. It may have direct effects on tissues such as nerve tissue and blood vessels, it may trigger other cells to produce other pathogenic substances and it may trigger release of more TNF- α both by inflammatory cells and also by Schwann-cells locally in the nerve tissue (65).]here is thus reason to believe that even low amounts of TNF- α may be sufficient to initiate these processes and that there is a local recruitment of cytokine producing cells and a subsequent increase in production and release of other cytokines as well as TNF- α . TNF- α may therefore act as the "ignition key" of the pathophysiologic processes and play an important role for the initiation of the pathophysiologic cascade behind the nucleus pulposus-induced nerve injury. However, the major contribution of TNF- α may be derived from recruited, aggregated and maybe even extravasated leukocytes, and that successful pharmacologic block may be achieved only by systemic treatment.

In conclusion, although the exact role of TNF- α can not be fully understood from the

experimental set-up, we may conclude that for the first time a specific substance (TNF- α) has been linked to the nucleus pulposus-induced nerve root injury. This new information may be of significant importance for the continued understanding of nucleus pulposus-induced nerve injury as well as raising the question of the potential future clinical use of pharmacological interference with TNF- α and related substances, for treatment of sciatica.

The presence of TNF- α in pig nucleus pulposus-cells was thus immunohistochemically verified. Block of TNF- α by a locally applied monoclonal antibody partially limited the nucleus pulposus-induced reduction of nerve root conduction velocity, whereas intravenous treatment with doxycycline, infliximab, and etanercept significantly blocked this reduction. These data for the first time links one specific substance, TNF- α , to the nucleus pulposus-induced nerve injury.

Aminoguanidine has showed to inhibit the release of nitrogen oxide (NO) at nerve root injuries by inhibiting inducible nitrogen oxide synthetase, and aminoguanidine is thus one compound that inhibits a compound triggered by the release of TNF- α .

The compounds of the invention can be administered in a variety of dosage forms, e.g., orally, in the form of tablets, capsules, sugar or film coated tablets, liquid solutions; rectally, in the form of suppositories; parenterally, e.g., intramuscularly or by intravenous injection or infusion. The therapeutic regimen for the different clinical syndromes must be adapted to the type of pathology taken in to account, as usual, also the route of administration, the form in which the compound is administered and age, weight, and condition of the subject involved.

The oral route is employed, in general, for all conditions, requiring such compounds. In emergency cases preference is given to intravenous injection. For these purposes the compounds of the invention can be administered orally at doses ranging from about 20 to about 1500 mg/day. Of course, these dosage regimens may be adjusted to provide the optimal therapeutic response.

The nature of the pharmaceutical composition containing the compounds of the invention in association with pharmaceutically acceptable carriers or diluents will, of course, depend upon the desired route of administration. The composition may be formulated in the

conventional manner with the usual ingredients. For example, the compounds of the invention may be administered in the form of aqueous or oily solutions or suspensions, tablets, pills, gelatine capsules (hard or soft ones) syrups, drops or suppositories.

5 Thus for oral administration, the pharmaceutical compositions containing the compounds of the invention are preferably tablets, pills or gelatine capsules, which contain the active substance together with diluents, such as lactose, dextrose, sucrose, mannitol, sorbitol, cellulose; lubricants, e.g., silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; or they may also contain binders, such as starches, gelatine, methyl
10 cellulose, carboxymethylcellulose, gum arabic, tragacanth, polyvinylpyrrolidone; disaggregating agents such as starches, alginic acid, alginates, sodium starch glycolate, microcrystalline cellulose; effervescing agents such as carbonates and acids; dyestuffs; sweeteners; wetting agents, such as lecithin, polysorbates, laurylsulphates; and in general non-toxic and pharmaceutically inert substances used in the formulation of pharmaceutical
15 compositions. Said pharmaceutical compositions may be manufactured in known manners, e.g., by means of mixing, granulating, tableting, sugar-coating or film-coating processes. In the case film providing compounds can be selected to provide release in the right place in the intestinal tract with regard to absorption and maximum effect. Thus pH-dependent film formers can be used to allow absorption in the intestines as such, whereby different phthalate
20 are normally used or acrylic acid/methacrylic acid derivatives and polymers.

The liquid dispersions for oral administration may be e.g., syrups, emulsion, and suspensions.

25 The syrups may contain as carrier, e.g., saccharose, or saccharose with glycerine and/or mannitol and/or sorbitol.

Suspensions and emulsions may contain as carrier, e.g., a natural gum, such as gum arabic, xanthan gum, agar, sodium alginate, pectin, methyl cellulose, carboxymethylcellulose,
30 polyvinyl alcohol.

The suspension or solutions for intramuscular injections may contain together with the active compound, a pharmaceutically acceptable carrier, such as e.g., sterile water, olive oil,

ethyl oleate, glycols,, e.g., propylene glycol, and if so desired, a suitable amount of lidocaine hydrochloride. Adjuvants for triggering the injection effect can be added as well.

5 The solutions for intravenous injection or infusion may contain as carrier, e.g., sterile water, or preferably, a sterile isotonic saline solution, as well as adjuvants used in the field of injection of active compounds.

10 The suppositories may contain together with the active compound, a pharmaceutically acceptable carrier, e.g., cocoa-butter polyethylene glycol, a polyethylene sorbitan fatty acid ester surfactant or lecithin.

REFERENCES

1. Amin AR, Attur MG, Thakker GD, Patel PD, Vyas PR, Patel RN, Patel IR, Abramson
5 SB. A novel mechanism of action of tetracyclines: effects on nitric oxide syntheses. Proc
Natl Acad Sci U S A 1996; **93**:14014-9.
2. Arai I, Konno S, Otani K, Kikuchi S, Olmarker K. Cyclosporin A blocks the toxic effects
of nucleus pulposus on spinal nerve roots. Manuscript
3. Arai I, Mao GP, Otani K, Konno S, Kikuchi S, Olmarker K. Indomethacin blocks nucleus
10 pulposus related effects in adjacent nerve roots. Manuscript
4. Baumgartner RA, Deramo VA, Beaven MA. Constitutive and inducible mechanisms for
synthesis and release of cytokines in immune cell lines. J Immunol 1996; **157**:4087-93.
5. Bidani A, Heming TA. Effects of lidocaine on cytosolic pH regulation and stimulus-
induced effector functions in alveolar macrophages. Lung 1997; **175**:349-61.
- 15 6. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ,
Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis
R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP. A metalloproteinase
disintegrin that releases tumour-necrosis factor- α from cells. Nature 1997; **385**:729-33.
7. Bluthe RM, Dantzer R, Kelley KW. Interleukin-1 mediates behavioural but not metabolic
20 effects of tumor necrosis factor alpha in mice. Eur J Pharmacol 1991; **209**:281-3.
8. Brattsand R, Linden M. Cytokine modulation by glucocorticoids: mechanisms and actions
in cellular studies. Aliment Pharmacol Ther 1996; **10**:81-90.
9. Byröd G, Otani K, Rydevik B, Olmarker K. Acute increase in endoneural vascular
permeability induce by epidural application of nucleus pulposus on spinal nerve roots.
25 Manuscript
10. Chao CC, Hu S, Ehrlich L, Peterson PK. Interleukin-1 and tumor necrosis factor-alpha
synergistically mediate neurotoxicity: involvement of nitric oxide and of N-methyl-D-
aspartate receptors. Brain Behav Immun 1995; **9**:355-65.
11. Dawson J, Hurtenbach U, MacKenzie A. Cyclosporin A inhibits the in vivo production
30 of interleukin-1beta and tumour necrosis factor alpha, but not interleukin-6, by a T-cell-
independent mechanism. Cytokine 1996; **8**:882-8.
12. DeLeo JA, Colburn RW, Rickman AJ. Cytokine and growth factor
immunohistochemical spinal profiles in two animal models of mononeuropathy. Brain Res

1997;759:50-7.

13. Gadiant RA, Cron KC, Otten U. Interleukin-1 beta and tumor necrosis factor-alpha synergistically stimulate nerve growth factor (NGF) release from cultured rat astrocytes.

Neurosci Lett 1990;117:335-40.

- 5 14. Garcia-Vicuna R, Diaz-Gonzalez F, Gonzalez-Alvaro I, del Pozo MA, Moilinedo F, Cabanas C, Gonzalez-Amaro R, Sanchez-Madrid F. Prevention of cytokine-induced changes in leucocyte adhesion receptors by nonsteroidal antiinflammatory drugs from the oxicam family. Arthritis Rheum 1997;40:143-53.

15. Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, Drummond AH, Galloway WA, Gilbert R, Gordon JL, et al. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 1994;370:555-7.

16. Gazelle EJ, Banda MJ, Leppert D. Matrix metallo-proteinases in immunity. J Immunol 1996; 156: 14.

- 15 17. Gonzalez E, de la Cruz C, de Nicolas R, Egido J, Herrero-Beaumont G. Long-term effect of nonsteroidal anti-inflammatory drugs on the production of cytokines and other inflammatory mediators by blood cells of patients with osteosis. Agents Actions 1994;41:171-8.

18. Hartung HP, Jung S, Stoll G, Zielasek J, Schmidt B, Archelos JJ, Toyka KV. Inflammatory mediators in demyelinating disorders of the CNS and PNS. J Neuroinuninol 20 1992;40:197-210.

19. Hattori A, Iwasald S, Murase K, Tsujimoto M, Sato M, Hayashi K, Kohno M. Tumor necrosis factor is markedly synergistic with interleukin I and ii3terferon-gamma in stimulating the production of nerve growth factor in fibroblasts. FEBS Lett 1994;340:177-80.

- 25 20. Herman JH, Sowder WG, Hess EV. Nonsteroidal antiinflammatory drug modulation of prosthesis pseudomembrane induced bone resorption. J Rheunutol 1994;21:338-43.

21. Iwamoto S, Takeda K. [Possible cytotoxic mechanisms of TNF in vitro]. Hum Cell 1990;3:107-12.

22. Jurd KM, Stephens CJ, Black MM, Hunt BJ. Endothelial cell activation in cutaneous vasculitis. Clin Exp Dermatol 1996;21:28-32.

23. Kawakami M, Tamaki T, Weinstein JN, Hashizume H, Nishi H, Meller ST. Pathomechanism of pain-related behaviour produced by allografts of intervertebral disc in the rat. Spine 1996;21:2101-7.

24. Kayama S, Konno S, Olmarker K, Yabuki S, Kikuchi S. Incision of the anulus fibrosis induces nerve root morphologic, vascular, and functional changes. An experimental study. Spine 1996;**21**:2539-43.
25. Kayama S, Olmarker K, Larsson K, Sjögren-Jansson E, Lindahl A, Rydevik B. Cultured, autologous nucleus pulposus cells induce structural and functional changes in spinal nerve roots. Spine, 1998, 23:90:2155-58,
26. Kloppenburg M, B~an BM, de Rooij-Dijk HH, Miltenburg AM, Daha MR, Breedveld FC, Dijkmans BA, Verweij C. The tetracycline derivative minocycline differentially affects cytokine production by monocytes and T lymphocytes. Antimicrob Agents Chemother 1996;**40**:934-40.
27. Kloppenburg M, Verweij CL, Miltenburg AM, Verboeven AJ, Daha MR, Dijkmans BA, Breeveld FC. The influence of tetracyclines on T cell activation. Clin Exp Immunol 1995;**102**:635-41.
28. Lamster IB, Pullman JR, Celenti RS, Grbic JT. The effect of tetracycline fiber therapy on beta-glucuronidase and interleukin-1 beta in crevicular fluid. J Clin Periodontol 1996;**23**:816-22.
29. Liberski PP, Yanagihara R, Nerurkar V, Gajdusek DC. Further ultrastructural studies of lesions induced in the optic nerve by tumor necrosis factor alpha (TNF- α): a comparison with experimental Creutzfeldt-Jakob disease. Acta Neurobiol Exp (Warsz) 1994;**54**:209-18.
30. Lin XH, Kashima Y, Khan M, Heller KB, Gu XZ, Sadun AA. An immunohistochemical study of TNF- α in optic nerves from AIDS patients. Curr Eye Res 1997;**16**:1064-8.
31. Madigan MC, Sadun AA, Rao NS, Dugel PU, Tenhula WN, Gill PS. Tumor necrosis factor-alpha (TNF- α)-induced optic neuropathy in rabbits. Neurol Res 1996; **18**:176-84.
32. Matsumori A, Ono K, Nishio R, Nose Y, Sasayama S. Amiodarone inhibits production of tumor necrosis factor-alpha by human mononuclear cells: a possible mechanism for its effect in heart failure. Circulation 1997;**96**:1386-9.
33. Milano S, Arcoleo F, D'Agostino P, Cillari E. Intraperitoneal injection of tetracyclines protects mice from lethal endotoxemia downregulating inducible nitric oxide synthase in various organs and cytokine and nitrate secretion in blood. Antimicrob Agents Chemother 1997;**41**:117-21.
34. Nawroth P, Handley D, Matsueda G, De Waal R, Gerlach H, Blohm D, Stem D. Tumor necrosis factor/cachectin-induced intra vascular fibrin formation in meth A fibrosarcomas. J Exp Med 1988;**168**:637-47.

35. Oka T, Wakugawa Y, Hosoi M, Oka K, Hori T. Intracerebroventricular injection of tumor necrosis factor-alpha induces thermal hyperalgesia in rats. Neuroimmunomodulation 1996;3:135-40.
36. Olmarker K, Blomquist J, Stromberg J, Nannmark, U, Thomsen P, Rydevik B. Inflammation-togenic properties of nucleus pulposus. Spine 1995;20:665-9.
- 5 37. Olmarker K, Brisby H, Yabuki S, Nordborg C, Rydevik B. The effects of normal, frozen, and hyaluronidase-digested nucleus pulposus on nerve root structure and function. Spine 1997;22:4715; discussion 476.
38. Olmarker K, Byrod G, Comefjord M, Nordborg C, Rydevik B. Effects of methylprednisolone on nucleus pulposus-induced nerve root injury. Spine 1994; 19:1803-8.
- 10 39. Olmarker K, Iwabuchi M, Larsson K, Rydevik B. Effects of in vitro degenerated nucleus pulposus on nerve root conduction velocity. Manuscript
40. Olmarker K, Myers RR. Pathogenesis of sciatic pain: Role of herniated nucleus pulposus and deformation of spinal nerve root and DRG. Pain, 1998, 78:9-105
- 15 41. Olmarker K, Nordborg C, Larsson K, Rydevik B. Ultrastructural changes in spinal nerve roots induced by autologous nucleus pulposus. Spine 1996;21:411-4.
42. Olmarker K, Rydevik B, Nordborg C. Autologous nucleus pulposus induces neurophysiologic and histologic changes in porcine cauda equina nerve roots [see comments]. Spine 1993;18:1425-32.
- 20 43. Otani K, Arai I, Mao GP, Konno S, Olmarker K, Kikuchi S. Nucleus pulposus-induced nerve root injury. The relationship between blood flow and nerve conduction velocity. Manuscript
44. Otani K, Mao GP, Arai I, Konno S, Olmarker K, Kikuchi S. Nucleus pulposus-induced increase in vascular permeability in the nerve root. Manuscript
- 25 45. Petrovich MS, Hsu HY, Gu X, Dugal P, Heller KB, Sadun AA. Pentoxifylline suppression of TNF- alpha mediated axonal degeneration in the rabbit optic nerve. Neuro Res 1997; 19:551-4.
46. Pichler WJ, Zanni M, von Greyerz S, Schnyder B, Mauri-HeUweg D, Wendland, T. High IL-5 production by human drug-specific T cell clones. Int Arch Allergy Immunol 1997; 1 13 :177-80.
- 30 47. Redford EJ, Hall SM, Smith KJ. Vascular changes and demyelination induced by the intra neural injection of tumour necrosis factor. Brain 1995; 1 18 :869-78.

48. Robache-Gallea S, Bruneau JM, Robbe H, Morand V, Capdevila C, Bhatnagar N, Chouaib S, Roman-Roman S. Partial purification and characterization of a tumor necrosis factor- alpha converting activity. Eur J Immunol 1997;**27**:1275-82.
49. Rosendahl MS, Ko SC, Long DL, Brewer MT, Rosenzweig B, Hedl E, Anderson L, Pyle SM, Moreland J, Meyers MA, Kohno T, Lyons D, Lichenstein HS. Identification and characterization of a pro-tumor necrosis factor- alpha-processing enzyme from the ADAM family of zinc metalloproteases. J Biol Chem 1997;**272**:24588-93.
50. Said G, Hontebeyrie-Joskowicz M. Nerve lesions induced by macrophage activation. Res Immunol 1992;**143**:589-99.
51. Sehnaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988;**23**:339-46.
52. Shapira L, Houry Y, Barak V, Halabi A, Soskoine WA, Stabholz A. Human monocyte response to cementum extracts from periodontally diseased teeth: effect of conditioning with tetracycline. J Periodontol 1996;**67**:682-7.
53. Shapira L, Houry Y, Barak V, Soskolne WA, Halabi A, Stabholz A. Tetracycline inhibits Porphyromonas gingivalis lipopolysaccharide- induced lesions in vivo and TNF α processing in vitro. J Periodontal Res 1997;**32**:183-8.
54. Sharief MK, Ingram DA, Swash M. Circulating tumor necrosis factor-alpha correlates with electrodiagnostic abnormalities in Guillain-Barre syndrome. Ann Neurol 1997;**42**:68-73.
55. Smith CS, Ortega G, Parker L, Shearer WT. Cyclosporin A blocks induction of tumor necrosis factor-alpha in human B lymphocytes. Biochem Biophys Res Commun 1994;**204**:383-90.
56. Sonuner C, Schmidt C, George A, Toyka KV. A metalloprotease-inhibitor reduces pain associated behaviour in mice with experimental neuropathy. Neurosci Lett 1997;**237**:45-8.
57. Sorkin LS, Xiao WH, Wagner R, Myers RR. Tumour necrosis factor-alpha induces ectopic activity in nociceptive primary afferent fibres. Neuroscience 1997;**81**:255-62.
58. Steinmeyer J, Daufeldt S, Taiwo YO. Pharmacological effect of tetracyclines on proteoglycanases from interleukin-1-treated articular cartilage. Biochem Pharmacol 1998;**55**:93-100.
59. Stoll G, Jung S, Jander S, van der Meide P, Hartung HP. Tumor necrosis factor-alpha in immunomediated demyelination and Wallerian degeneration of the rat peripheral nervous system. Neuroimmunol 1993;**45**:175-82.

60. Takao Y, Mikawa K, Nishina K, Maekawa N, Obara H. Lidocaine attenuates hyperoxic lung injury in rabbits. Acta Anaesthesiol Scand 1996;40:318-25.
61. Teoh KH, Bradley CA, Galt J, Burrows H. Steroid inhibition of cytokine-mediated vasodilation after warm heart surgery. Circulation 1995;92:II347-53.
- 5 62. Tsukamoto T, Ishikawa M, Yamamoto T. Suppressive effects of TNF- α on myelin formation in vitro. Acta Neurol Scand 1995;91:71-5.
63. van der Poll T, Jansen PM, Van Zee KJ, Welborn MBr, de Jong I, Hack CE, Loetscher H, Lesslauer W, Lowry SF, Moidawer LL. Tumor necrosis factor-alpha induces activation of coagulation and fibrinolysis in baboons through an exclusive effect on the p55 receptor.
- 10 Blood 1996;88:922-7.
64. Villarroja H, Violleau K, Ben Younes-Chennoufi A, Baumann N. Myelin-induced experimental allergic encephalomyelitis in Lewis rats: tumor necrosis factor alpha levels in serum of cerebrospinal fluid immunohistochemical expression in glial cells and neurophages of optic nerve and spinal cord. J Neuroimmunol 1996;64:55-61.
- 15 65. Wagner R, Myers RR. Schwann cells produce tumor necrosis factor alpha: expression in injured non-injured nerves. Neuroscience 1996;73:625-9.
66. Wagner R, Myers RR. Endoneurial injection of TNF- α produces neuropathic pain behaviours. Neuroreport 1996;7:2897-901.
67. Wasaki S, Sakaida I, Uchida K, Kiinura T, Kayano K, Okita K. Preventive effect of cyclosporin A on experimentally induced acute liver injury in rats. Liver 1997; 17:107-14.
- 20 68. Wershil BK, Furuta GT, Lavigne JA, Choudhury AR, Wang ZS, Galli SJ. Dexamethasone cyclosporin A suppress mast cell-leukocyte cytokine cascades by multiple mechanisms. Int Arch Allergy Immunol 1995;107:323-4.
69. Yabuki S, Kawaguchi Y, Olmarker K, Rydevik B. Effects of lidocaine on nucleus
- 25 pulposus-induced nerve root injury. Spine, 1998, 23:29:2383-89
70. Zhu J, Bai XF, Mix E, Link H. Cytokine dichotomy in peripheral nervous system influences the outcome of experimental allergic neuritis: dynamics of mRNA expression for IL-1 beta, IL-6, IL-10, IL-12, TNF- α , TNF-beta, and cytolysin. Clin Immunol Immunopathol 1997;84:85-94.

CLAIMS

1. Use of a TNF- α inhibitor selected from the group consisting of metallo proteinase inhibitors excluding methylprenisolone, tetracyclines including chemically modified tetracyclines, quinolones, corticosteroids, thalidomide, lazaroïdes, pentoxiphyllines,
5 hydroxamic acid derivatives, carbocyclic acids, naphthopyrans, soluble cytokine receptors, monoclonal antibodies towards TNF- α , amrinone, pimobendan, vesnarinone, phosphodiesterase III inhibitors, lactoferrin and lactoferrin derived analogous, and melatonin in the form of the base or its addition salt, in the preparation of a pharmaceutical composition for the treatment of spinal disorders as nerve root injury caused by the
10 liberation of TNF- α and compounds triggered by the liberation of or presence of TNF- α by inhibiting spinal disk TNF- α .
2. Use according to claim 1, wherein the active component is selected from the group consisting of tetracycline, doxycycline, lymecycline, oxytetracycline, minocycline, and
15 chemically modified tetracyclines dedimethylaminotetracycline, in the form of bases or addition salts.
3. Use according to claim 2, wherein the active component is doxycycline.
- 20 4. Use according to claim 1, wherein the active component is selected from hydroxamic acid compounds, carbocyclic acids and derivatives, thalidomide, lazaroïdes, pentoxiphylline, naphthopyrans, soluble cytokine receptors, monoclonal antibody towards TNF- α , amrinone, pimobendan, vesnarinone, phosphodiesterase III inhibitors, melatonin in the form of bases or addition salts.
25
5. Use according to claim 1, wherein the active component is selected from norfloxacin, ofloxacin, ciprofloxacin, gatifloxacin, pefloxacin, lomefloxacin, and temafloxacin in the form of bases or addition salts.
- 30 6. Use according to claim 1, wherein the active component is a metallo proteinase inhibitor in the form of base or addition salts.
7. Use according to claim 1, wherein the active component comprises a substance inhibiting a

compound triggered by the release of TNF- α , such as interferon-gamma, interleukin-1, and nitrogen oxide (NO) in the form of base or addition salts

8. Method for the treatment of spinal disorders as nerve root injury caused by the liberation
- 5 of TNF- α in mammals, including man, comprising the administration of a pharmaceutically effective amount of a TNF- α inhibitor selected from the group consisting of metallo proteinase inhibitors excluding methylprednisolone, tetracyclines including chemically modified tetracyclines, quinolones, corticosteroids, thalidomide, lazaroïdes,
- 10 pentoxyphylline, hydroxamic acid derivatives, carbocyclic acids, naphopyrans, soluble cytokine receptors, monoclonal antibodies towards TNF- α , amrinone, pimobendan, vesnarinone, phosphodiesterase III inhibitors, lactoferrin and lactoferrin derived analogous, and melatonin in the form of the base or its addition salt.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 99/01671

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61K 31/65, A61K 31/56, A61K 31/33, A61K 31/16, A61K 31/19, A61P 25/00
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61K, A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	STN International, File MEDLINE, MEDLINE accession no. 97218877, Document no. 97218877, Schlumpf U et al: "Acute lumbar disk displacement with nerve root compression. Indications for peridural steroid injection."; SCHWEIZERISCHE RUNDSCHAU FUR MEDIZIN PRAXIS, (1997 Feb 18) 86 (8) 292-5 --	1,6-8
X	STN International, File MEDLINE, MEDLINE accession no. 76231109, Document no. 76231109, Schenk S et al: "Intrathecal cortison injection in lumbar disc problems"; ARCHIV FUR ORTHOPADISCHE UND UNFALL-CHIRURGIE, (1976 Jun 18) 85 (1) 21-31 --	1,6-8

☒ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier document but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

13 January 2000

Date of mailing of the international search report

29 -01- 2000

Name and mailing address of the ISA/
 Swedish Patent Office
 Box 5055, S-102 42 STOCKHOLM
 Facsimile No. +46 8 666 02 86

Authorized officer

Solveig Gustavsson/ELY
 Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 99/01671

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	STN International, File EMBASE, EMBASE accession no. 97339851, Document no. 1997339851, Kraemer J. et al: "Lumbar epidural perineural injection: A new technique"; European Spine Journal, (1997) 6/5 (357-361) --	1,6-8
X	STN International, File MEDLINE, MEDLINE accession no. 95064276, Document no. 95064276, Olmarker K. et al: "Effects of methylprednisolone on nucleus pulposus-induced nerve root injury"; SPINE (1994 Aug 15) 19 (16) 1803-8 --	1,6-8
X	STN International, File MEDLINE, MEDLINE accession no. 96310878, Document no. 96310878, Pennica, D. et al: "Cardiotrophin-1, a cytokine present in embryonic muscle, supports long-term survival of spinal motoneurons"; NEURON, (1996 Jul) 17 (1) 63-74 --	1,7-8
X	STN International, File MEDLINE, MEDLINE accession no. 1998068711, Document no. 98068711, Sommer C. et al: "A metalloprotease-inhibitor reduces pain associated behavior in mice with experimental neuropathy"; NEUROSCIENCE LETTERS, (1997 Nov 14) 237 (1) 45-8 --	1,4,6-8
X	STN International, File MEDLINE, MEDLINE accession no. 1998173500, Document no. 98173500, Sommer C. et al: "The effect of thalidomide treatment on vascular pathology and hyperalgesia caused by chronic constriction injury of rat nerve"; PAIN, (1998 Jan) 74 (1) 83-91 --	1,4,6-8
P,X	STN International, File MEDLINE, MEDLINE accession no. 1999071916, Document no. 99071916, Olmarker K. et al: "Tumor necrosis factor alpha and nucleus-pulposus-induced nerve root injury"; SPINE, (1998 Dec 1) 23 (23) 2538-44 -- -----	1-3,6-8

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE99/01671

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: **8**
because they relate to subject matter not required to be searched by this Authority, namely:
See extra sheet.
2. ☒ Claims Nos.: **1 and 7-8**
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
It is not clear from the wording of the claims, what is excluded from or included in the claimed invention.

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE99/01671

Claim 8 relate to a method of treatment of the human or animal body by surgery or by therapy/a diagnostic method practised on the human or animal body/ Rule. 39.1.(iv). Nevertheless, a search has been executed for this claim. The search has been based on the alleged effects of the compound(s)/composition(s).



RESPONSE TO WRITTEN OPINION

Handled by
Maria Stenbäck

Göteborg
22 December 2000

Our ref.
PC-2006988

Application No.
PCT/SE99/01671

Attention

**PATENT- OCH REGISTRERINGSVERKET
INTERNATIONELLA SEKTIONEN
STOCKHOLM**

International Application No. PCT/SE99/01671
Applicants: A⁺ SCIENCE INVEST AB et al

Dear Sirs,

In response to the Written Opinion mailed 30 October 2000, for which the time limit for response was extended until 31 December 2000 during a telephone conversation with the Examiner on 7 December, we submit a new set of claims on pages 22-26 which are to replace the originally filed claims. The old page 24 with the abstract is thus to be renumbered page 27.

In the new set of claims claim 1 corresponds to the old claim 1, but the different TNF- α inhibitors have been split into subparagraphs to make it clearer. That this is what is intended by the earlier wording is clear from the description, and man skilled in the art also easily understands this. Also claim 21, which corresponds to the old claim 8, has been adjusted correspondingly.

To further clarify the claims, the expression "active compound" used in the subclaims has been replaced by "TNF- α inhibitor" since this is the active compound according to the invention.

GÖTEBORG		VAT No.	SE556082702301	Other offices:	
STREET ADDRESS:	POSTAL ADDRESS:	Telephone	+46 31 63 02 00	MALMÖ (Head office and registered office)	
Södra Hamngatan 37 - 41	Box 11394	Fax	+46 31 63 02 63	HALMSTAD	HELSINGBORG
GÖTEBORG	SE-404 28 GÖTEBORG	Email	mail@awapatent.com	LIDKÖPING	STOCKHOLM
SWEDEN	SWEDEN	Homepage	www.awapatent.com	SÖDERHAMN	ÖSTERSUND
				VÄXJÖ	

In the new independent claim 2, one of the TNF- α inhibitors, namely soluble cytokine receptors, from the old claim 1 and the old claim 4 has been specified.

Similarly, in the new independent claim 4, one of the TNF- α inhibitors, namely monoclonal antibodies, from the old claim 1 and the old claim 4 has been specified.

In the new claim 3 it is specified that the TNF- α inhibitor is the soluble cytokine receptor etanercept. The support for this is found in the example, wherein etanercept (Enbrel^R) is used in series 3, and man skilled in the art knows that etanercept is a soluble cytokine receptor.

In the new claim 5 it is specified that the TNF- α inhibitor is the monoclonal TNF- α antibody infliximab. The support for this is found in the example, wherein infliximab (Remicade^R) is used in series 3.

The new claim 6 corresponds to the old claim 2.

The new claim 7 corresponds to the old claim 3

The new claim 8 corresponds to the old claim 4, from which monoclonal antibodies and soluble cytokine receptors have been removed.

The new claim 9 corresponds to the old claim 5.

The new claim 10 corresponds to the old claim 6.

The new claim 11 corresponds to the old claim 7. However, it has been rewritten so that it is an independent claim, since the reference to TNF- α inhibitors is incorrect. The support for this is found i.a. on pages 11-13.

- Nerve compression is usually not painful. A compressed nerve in the arm or leg only results in reduced motor and sensory nerve activity, i.e. muscular weakness and decreased sensibility. This is in sharp contrast to sciatica where the predominant symptom is sharp and intense pain, radiating out into the lower extremity.

- The conclusion the inventors made was that there must be another component that may render the nerves to be sensitive to the applied compression and, thus unlike other nerve compression syndromes, produce pain. The inventors assumed that this unknown factor would be part of the herniated disc, and in 1993 they could demonstrate that application of disk tissue (nucleus pulposus) induced a reduction in motor nerve conduction in the absence of mechanical compression (see Olmarker K, Rydevik B, Nordborg C. Autologous nucleus pulposus induces neurophysiologic and histologic changes in porcine cauda equina nerve roots. Spine 1993;18:1425-32). In 1998 they could demonstrate nucleus pulposus sensitised the nerve root to produce pain when it was compressed, whereas compression alone did not induce pain (see Olmarker K, Myers RR. Pathogenesis of sciatic pain: role of herniated nucleus pulposus and deformation of spinal nerve root and dorsal root ganglion. Pain 1998;78:99-105). However, it was completely unknown which component of the nucleus pulposus induced these changes until the present invention was made.

Document D1: abstract of STN International, File MEDLINE, Accession No. 97218877
Document D2: abstract of STN International, File MEDLINE, Accession No. 76231109
Document D3: abstract of STN International, File MEDLINE, Accession No. 96310878
Document D4: abstract of STN International, File MEDLINE, Accession No. 98068711
Document D5: abstract of STN International, File MEDLINE, Accession No. 98173500
Document D6: abstract of STN International, File EMBASE, Accession No. 97339851
Document D7: abstract of STN International, File MEDLINE, Accession No. 95064276

DOI: 10.1111/j.1365-3113.2015.04636.x

D1:

Inflammatory mechanisms may in some way may be related to the induction of the sciatica symptoms. In order to reduce the inflammation, the authors of D1 have tried to use non-specific anti-inflammatory treatment, either orally (NSAID) or by local injection (cortisone, lidocain). At the time D1 was written there was no knowledge that TNF was involved in the pathophysiology, and the circumstance that methyl-prednisolone, among many other effects, may also induce slight non-specific TNF-inhibition must be considered as a coincidence with no intellectual link at that time. There was no knowledge that TNF was involved in sciatica until the present invention was made, and this was first published in December 1998 in a publication in Spine (Olmarker K, Larsson K. Tumor necrosis factor alpha and nucleus-pulposus-induced nerve root injury. Spine 1998;23:2538-44), i.e. after the priority date of the present application.

D2:

The same comment as for D1 are applicable also to this paper.

D3:

This is a paper regarding in vitro studies of sciatic neurons. "Sciatic" in this context refers to the sciatic nerve that is located in the thigh. Since sciatica is characterized by pain in the thigh and calf, it was earlier believed that the pain was due to an injury of the local nerve, i.e. the sciatic nerve. D3 has therefore no connection to "sciatica". D3 also mentions "cytokine receptors" but this is not linked to TNF and D3 only suggests that there may be action of an unknown cytokine that may explain the data.

For your information, it was not until 1934 that it was understood that sciatica was due to a nerve injury at the level of the lumbar spine, as published in the very well known paper by Mixter WJ, Barr JS. Rupture of the intervertebral disc with involvement of the spinal canal. N Engl J Med 1934;211:210-215 (enclosed).

D4:

This paper studies the action of TNF inhibitors after mechanical compression. D4 thus not related to the invention that discloses that TNF is mediating the non-mechanical effects in-

ask you to please quote this reference in future correspondence. We also refer to our fax sent 15 December 2000, where we ask you to disregard the letter dated 13 December from the earlier agent since they were no longer representing the Applicants at this date.

Yours faithfully,



Maria Stenbäck

Authorised Agent

AWAPATENT AB

Encls.

1. Ameded claims
2. Mixter WJ, Barr JS. Rupture of the intervertebral disc with involvement of the spinal canal. N Engl J Med 1934; 211:210-215

CLAIMS

1. Use of a TNF- α inhibitor selected from the group consisting of:

- 5 - metallo proteinase inhibitors excluding methylprenis-olone,
- tetracyclines including chemically modified tetracyclines,
- quinolones,
- 10 - corticosteroids,
- thalidomide,
- lazaroides,
- pentoxiphyllines,
- hydroxamic acid derivatives,
- 15 - carbocyclic acids,
- naphthopyrans,
- soluble cytokine receptors,
- monoclonal antibodies towards TNF- α ,
- amrinone,
- 20 - pimobendan,
- vesnarinone,
- phosphodiesterase III inhibitors,
- lactoferrin and lactoferrin derived analogous, and
- melatonin
- 25 in the form of the base or its addition salt,
- in the preparation of a pharmaceutical composition for the treatment of spinal disorders as nerve root injury caused by the liberation of TNF- α and compounds triggered by the liberation of or presence of TNF- α by inhibiting
- 30 spinal disk TNF- α .

2. Use of a TNF- α inhibitor in the form of a soluble cytokine receptor in the preparation of a pharmaceutical composition for the treatment of spinal disorders as nerve root injury caused by the liberation of TNF- α
- 35 and compounds triggered by the liberation of or presence of TNF- α by inhibiting spinal disk TNF- α .

3. Use according to claim 1 or 2, wherein the TNF- α inhibitor is the soluble cytokine receptor etanercept.

4. Use of a TNF- α inhibitor in the form of a monoclonal antibody towards TNF- α in the preparation of a pharmaceutical composition for the treatment of spinal disorders as nerve root injury caused by the liberation of TNF- α and compounds triggered by the liberation of or presence of TNF- α by inhibiting spinal disk TNF- α .

5. Use according to claim 1 or 4, wherein the TNF- α inhibitor is the monoclonal antibody infliximab.

6. Use according to claim 1, wherein the TNF- α inhibitor is selected from the group consisting of tetracycline, doxycycline, lymecycline, oxytetracycline, minocycline, and chemically modified tetracyclines dedimethylaminotetracycline, in the form of bases or addition salts.

7. Use according to claim 6, wherein the TNF- α inhibitor is doxycycline.

8. Use according to claim 1, wherein the TNF- α inhibitor is selected from hydroxamic acid compounds, carbocyclic acids and derivatives, thalidomide, lazaroïdes, pentoxyphylline, naphthopyrans, amrinone, pimobendan, vesnarinone, phosphodiesterase III inhibitors, melatonin in the form of bases or addition salts.

9. Use according to claim 1, wherein the TNF- α inhibitor is selected from norfloxacin, ofloxacin, ciprofloxacin, gatifloxacin, pefloxacin, lomefloxacin, and temafloxacin in the form of bases or addition salts.

10. Use according to claim 1, wherein the TNF- α inhibitor is a metallo proteinase inhibitor in the form of base or addition salts.

11. Use of a substance inhibiting a compound triggered by the release of TNF- α , such as interferon- γ , interleukin-1, and nitrogen oxide (NO), in the form of base or addition salts in the preparation of a pharmaceutical composition for the treatment of spinal disorders as nerve root injury caused by the liberation

13. Use according to any one of the claims 1-11, wherein said nerve root injury is nucleus pulposus-induced.

15. A pharmaceutical composition for the treatment of nerve root injury comprising a pharmaceutically effective amount of a soluble cytokine receptor.

17. A pharmaceutical composition for the treatment of nerve root injury comprising a pharmaceutically effective amount of a monoclonal antibody selective for TNF- α .

19. A method for partially blocking nucleus pulposus-induced reduction of nerve conduction velocity, comprising the administration of a blocking-effective amount of a monoclonal antibody selective for TNF- α .

21. A method for the treatment of spinal disorders as nerve root injury caused by the liberation of TNF- α in mammals, including man, comprising the administration of a pharmaceutically effective amount of a TNF- α inhibitor selected from the group consisting of:

- metallo proteinase inhibitors excluding methylprenis-
olone,
- tetracyclines including chemically modified tetracy-
clines,
- quinolones,
- corticosteroids,

- thalidomide,
- lazaroïdes,
- pentoxyphyllines,
- hydroxamic acid derivatives,
- 5 - carbocyclic acids,
- naphthopyrans,
- soluble cytokine receptors,
- monoclonal antibodies towards TNF- α ,
- amrinone,
- 10 - pimobendan,
- vesnarinone,
- phosphodiesterase III inhibitors,
- lactoferrin and lactoferrin derived analogous, and
- melatonin

15 in the form of the base or its addition salt.

22. A method for the treatment of spinal disorders as nerve root injury caused by the liberation of TNF- α in mammals, including man, comprising the administration of a pharmaceutically effective amount of a TNF- α inhibitor
20 in the form of a soluble cytokine receptor.

23. A method according to claim 21 or 22, wherein said TNF- α inhibitor is the soluble cytokine receptor etanercept.

24. A method for the treatment of spinal disorders
25 as nerve root injury caused by the liberation of TNF- α in mammals, including man, comprising the administration of a pharmaceutically effective amount of a TNF- α inhibitor in the form of a monoclonal antibody towards TNF- α .

25. A method according to claim 21 or 24, wherein
30 said TNF- α inhibitor is the monoclonal antibody infliximab.

26. A method according to claim 21, wherein the TNF- α inhibitor is selected from the group consisting of tetracycline, doxycycline, lymecycline, oxytetracycline,
35 minocycline, and chemically modified tetracyclines dedimethylaminotetracycline, in the form of bases or addition salts.

27. A method according to claim 26, wherein the TNF- α inhibitor is doxycycline.

28. A method according to claim 21, wherein the TNF- α inhibitor is selected from hydroxamic acid compounds, carbocyclic acids and derivatives, thalidomide, 5 lazaroides, pentoxyphylline, naphthopyrans, amrinone, pimobendan, vesnarinone, phosphodiesterase III inhibitors, melatonin in the form of bases or addition salts.

29. A method according to claim 21, wherein the 10 TNF- α inhibitor is selected from norfloxacin, ofloxacin, ciprofloxacin, gatifloxacin, pefloxacin, lomefloxacin, and temafloxacin in the form of bases or addition salts.

30. A method according to claim 21, wherein the 15 TNF- α inhibitor is a metallo proteinase inhibitor in the form of base or addition salts.

31. A method for the treatment of spinal disorders as nerve root injury caused by the liberation of TNF- α and compounds triggered by the liberation of or presence of 20 TNF- α in mammals, including man, comprising the administration of a pharmaceutically effective amount of a substance inhibiting a compound triggered by the release of TNF- α , such as interferon- γ , interleukin-1, and nitrogen oxide (NO), in the form of base or addition salts.

25 32. A method according to claim 21, wherein said nerve root injury is induced by disk herniation.

33. A method according to claim 21, wherein said nerve root injury is nucleus pulposus-induced.

34. A method according to claim 21, wherein said 30 nerve root injury is sciatica.